Endogena Therapeutics Program
Retinitis Pigmentosa
Key Facts
About Centenara Labs
Centenara Labs is a pioneering longevity-focused biotech that builds and invests in a diversified portfolio of companies targeting geriatric diseases through the lens of aging biology. Its strategy involves de-risking early scientific discoveries by providing a platform of experienced drug developers, business leaders, and capital. With a pipeline built around the hallmarks of aging, the company has progressed two ophthalmology programs into the clinic and is advancing several pre-clinical assets in fibrosis, cancer, and sarcopenia, aiming to create optimal exit scenarios to fund new ventures.
View full company profileAbout Centenara Labs
Centenara Labs is a pioneering longevity-focused biotech that builds and invests in a diversified portfolio of companies targeting geriatric diseases through the lens of aging biology. Its strategy involves de-risking early scientific discoveries by providing a platform of experienced drug developers, business leaders, and capital. With a pipeline built around the hallmarks of aging, the company has progressed two ophthalmology programs into the clinic and is advancing several pre-clinical assets in fibrosis, cancer, and sarcopenia, aiming to create optimal exit scenarios to fund new ventures.
View full company profileTherapeutic Areas
Other Retinitis Pigmentosa Drugs
| Drug | Company | Phase |
|---|---|---|
| OCU400 (AAV5-hNR2E3) | Ocugen | Phase 3 |